Eli Lilly (LLY) Reports Positive Foundayo Weight Loss Data for Menopausal Women

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy. On June 7, Eli Lilly’s oral GLP-1 medication, Foundayo (orforglipron), demonstrated significant efficacy in promoting weight loss for women across all stages of menopause. Results from post-hoc analyses of the ATTAIN-1 and ATTAIN-2 clinical trials, presented at the American Diabetes Association’s 86th Scientific Sessions, indicate that women taking the highest dose experienced substantial weight reduction regardless of whether they were pre-, peri-, or post-menopausal.

In the ATTAIN-1 trial, women achieved weight losses of up to 30.4 lbs (14.4%) in perimenopause and 28.2 lbs (14.1%) in post-menopause over 72 weeks. Similar trends were observed in the ATTAIN-2 trial, which included participants living with type 2 diabetes, where post-menopausal women saw weight loss of up to 27.8 lbs (13.6%). Additionally, participants across both studies reported meaningful reductions in waist circumference, suggesting a decrease in abdominal fat and associated cardiometabolic risks.

These findings address a critical gap in obesity care, as hormonal changes during menopause frequently accelerate fat accumulation and complicate weight management efforts. As a once-daily, non-peptide oral medication that does not require food or water restrictions, Foundayo offers a flexible treatment option for women navigating the biological challenges of this life stage.

Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products across cardiometabolic health, oncology, and immunology.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.